PM8002 Clinical Trials (2026): 13 Studies for SCLC & HCC

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

13 PM8002 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 11 indications (including SCLC & HCC) and 1,865 total planned enrollment. 2 Phase 3 PM8002 trials and 8 Phase 2 are listed. 6 PM8002 clinical trials are actively recruiting. Most recent activity: NCT06837948 (Dec 2031).

PM8002 clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingcompletednot yet recruitingTotal
P1/P21113
P214128
P3112

Recruiting PM8002 clinical trials (6)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT06837948Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLCP2Locally Advanced Non-Small Cell Lung Cancer160Feb 2025
NCT07133750BNT327PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerP2CRC (Colorectal Cancer)40Aug 2025
NCT06419621PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBCP3Triple Negative Breast Cancer(TNBC)360Jun 2024
NCT05879055A Study of PM8002 in Combination With Chemotherapy in Patients With NENP2Neuroendocrine Neoplasm60May 2023
NCT06584071A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCP1/P2HCC140Dec 2024
NCT05918445PM8002 in the Treatment of Patients With Advanced Solid TumorsP1/P2Malignant Neoplasm380Mar 2021

PM8002 clinical trials by indication

SCLC (3)

NCTAcronymPhaseStatusTitle
NCT06616532P3active not recruitingPM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
NCT05879068P2active not recruitingA Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
NCT05844150P2active not recruitingA Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

CRC (Colorectal Cancer) (1)

NCTAcronymPhaseStatusTitle
NCT07133750BNT327P2not yet recruitingPM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Locally Advanced Non-Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06837948P2not yet recruitingNeoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

HCC (1)

NCTAcronymPhaseStatusTitle
NCT06584071P1/P2not yet recruitingA Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

Triple Negative Breast Cancer(TNBC) (1)

NCTAcronymPhaseStatusTitle
NCT06419621P3recruitingPM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

NSCLC (1)

NCTAcronymPhaseStatusTitle
NCT05756972P2active not recruitingA Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC

Neuroendocrine Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT05879055P2recruitingA Study of PM8002 in Combination With Chemotherapy in Patients With NEN

MPM (1)

NCTAcronymPhaseStatusTitle
NCT05918107P2completedA Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

TNBC (1)

NCTAcronymPhaseStatusTitle
NCT05918133P1/P2active not recruitingA Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05864105P2active not recruitingPM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma

Malignant Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT05918445P1/P2recruitingPM8002 in the Treatment of Patients With Advanced Solid Tumors

PM8002 pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
BNT327NCT07133750P2not yet recruitingCRC (Colorectal Cancer)40

All PM8002 trials (13)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT06837948Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLCP2not yet recruiting160Shanghai Pulmonary Hospital, Shanghai, ChinaFeb 2025
NCT07133750BNT327PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerP2not yet recruiting40Biotheus Inc.Aug 2025
NCT06616532PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung CancerP3active not recruiting404Biotheus Inc.Nov 2024
NCT06419621PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBCP3recruiting360Biotheus Inc.Jun 2024
NCT05879055A Study of PM8002 in Combination With Chemotherapy in Patients With NENP2recruiting60Biotheus Inc.May 2023
NCT06584071A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCP1/P2not yet recruiting140Biotheus Inc.Dec 2024
NCT05918133A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBCP1/P2active not recruiting42Biotheus Inc.Jul 2022
NCT05864105PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaP2active not recruiting35Biotheus Inc.Apr 2022
NCT05879068A Study of PM8002 in Combination With Chemotherapy in Patients With SCLCP2active not recruiting99Biotheus Inc.May 2022
NCT05918107A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPMP2completed31Biotheus Inc.Aug 2022
NCT05756972A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLCP2active not recruiting64Biotheus Inc.Jun 2023
NCT05844150A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLCP2active not recruiting50Biotheus Inc.Jun 2023
NCT05918445PM8002 in the Treatment of Patients With Advanced Solid TumorsP1/P2recruiting380Biotheus Inc.Mar 2021

PM8002 clinical trials: frequently asked questions

How many PM8002 clinical trials are there?
13 PM8002 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 1 is marked completed.
Are PM8002 clinical trials recruiting in 2026?
Yes — 3 PM8002 trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
What conditions is PM8002 being studied for?
PM8002 is being studied for SCLC, HCC, Hepatocellular Carcinoma, Liver Cancer, Locally Advanced Non-Small Cell Lung Cancer and 7 more. The trials are grouped by indication on this page.
What phase is PM8002 in?
PM8002 clinical trials span 2 Phase 3, 8 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors PM8002 clinical trials?
The lead sponsor across the most PM8002 trials is Biotheus Inc., with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming PM8002as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: